Walleye Capital LLC Makes New Investment in CG Oncology, Inc. (NASDAQ:CGON)

Walleye Capital LLC bought a new position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 224,580 shares of the company's stock, valued at approximately $6,441,000. Walleye Capital LLC owned approximately 0.30% of CG Oncology as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of CG Oncology by 15.3% in the fourth quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company's stock valued at $168,096,000 after acquiring an additional 779,730 shares during the period. Wellington Management Group LLP lifted its stake in CG Oncology by 274.4% in the fourth quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock worth $54,792,000 after purchasing an additional 1,400,251 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of CG Oncology by 61.6% during the fourth quarter. Alliancebernstein L.P. now owns 1,817,887 shares of the company's stock valued at $52,137,000 after buying an additional 692,982 shares during the period. State Street Corp raised its holdings in shares of CG Oncology by 73.0% in the third quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after buying an additional 717,722 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of CG Oncology by 3.7% in the fourth quarter. Franklin Resources Inc. now owns 1,275,891 shares of the company's stock worth $36,593,000 after buying an additional 45,698 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Stock Up 3.3 %

Shares of NASDAQ CGON traded up $0.67 during trading hours on Monday, hitting $21.31. 61,097 shares of the stock were exchanged, compared to its average volume of 718,886. The company has a market cap of $1.62 billion, a PE ratio of -15.01 and a beta of 1.24. CG Oncology, Inc. has a 12 month low of $14.80 and a 12 month high of $46.99. The firm has a fifty day moving average price of $24.32 and a 200-day moving average price of $29.72.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. As a group, equities analysts anticipate that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CGON shares. Scotiabank assumed coverage on CG Oncology in a research note on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 target price on the stock. Morgan Stanley reissued an "overweight" rating and issued a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of CG Oncology in a research report on Monday, March 31st. Finally, TD Cowen initiated coverage on CG Oncology in a report on Tuesday, January 7th. They issued a "buy" rating for the company. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $59.33.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.